Colorectal Cancer

Van K. Morris, MD, discusses the recent progress made in the treatment of patients with BRAF-mutated metastatic colorectal cancer.

Scott Kopetz, MD, PhD, FACP, discusses the rationale and primary endpoints of the BEACON CRC study in BRAF V600E–mutant metastatic colorectal cancer.

Neil H. Segal, MD, PhD, discusses the current role of immunotherapy in colorectal cancer and the work being done to define its role in earlier-line settings and among patients with microsatellite stable disease.

The approval of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer is generating hopes that similar strategies also may be effective against HER2-expressing gastric and colorectal cancers, according to a panel of experts in gastrointestinal malignancies.

Cathy Eng, MD, FACP, FASCO, discusses the need to increase awareness regarding treating adolescents and young adults with colorectal cancer.

A. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses dual-immunotherapy strategies in colorectal cancer (CRC).

Ryan B. Corcoran, MD, PhD, discusses the presence of HER2 amplification in metastatic colorectal cancer.

Andrea Cercek, MD, discusses the need for treatment options in KRAS-mutated metastatic colorectal cancer (mCRC).

Andrea Cercek, MD, discusses the importance of molecular testing in colorectal cancer.